EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Avneet Singh, Adam Buckholz, Sonal Kumar, Carolyn Newberry

Nutrients · 2024

DOI: 10.3390/nu16050658 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2024. Verfasst von Avneet Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cooper University Hospital, Camden, NJ 08103, USA. Hauptthemen laut MEDLINE: Sarcopenia, Metabolic Diseases, Fatty Liver. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a common cause of chronic liver disease globally, with prevalence rapidly increasing in parallel with rising rates of obesity and metabolic syndrome. MASLD is defined by the presence of excess fat in the liver, which may induce inflammatory changes and subsequent fibrosis in high-risk patients. Though MASLD occurs frequently, there is still no approved pharmacological treatment, and the mainstay of therapy remains lifestyle modification via dietary changes, enhancement of physical activity, and management of metabolic comorbidities. Most nutrition research and clinical guidance in this disease centers on the reduction in fructose and saturated fat in the diet, although the emerging literature suggests that protein supplementation is important and implicates muscle mass and sarcopenia in disease-related outcomes. This review will assess the current data on these topics, with the goal of defining best practices and identifying research gaps in care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaMetabolic DiseasesFatty LiverHumansPrognosisBehavior Therapy

Stichwörter der Autor:innen

fatty liverhepatic steatosismalnutritionmetabolic dysfunction-associated steatotic liver diseasesarcopenia

Autor:innen und Institutionen

  • Department of Medicine, Cooper University Hospital, Camden, NJ 08103, USA.
  • Division of Gastroenterology, Weill Cornell Medical Center, New York, NY 10065, USA.

Zitieren

APA

Singh, A., Buckholz, A., Kumar, S., & Newberry, C. (2024). Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Nutrients. https://doi.org/10.3390/nu16050658

Vancouver

Singh A, Buckholz A, Kumar S, Newberry C. Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Nutrients. 2024. doi:10.3390/nu16050658

BibTeX
@article{Singh2024,
  author = {Singh, Avneet and Buckholz, Adam and Kumar, Sonal and Newberry, Carolyn},
  title = {Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16050658}
}
Kostenlos starten →